Information Provided By: 
Fly News Breaks for September 23, 2019
ACAD
Sep 23, 2019 | 07:16 EDT
Cantor Fitzgerald analyst Charles Duncan raised his price target for Acadia Pharmaceuticals to $56 from $49 and reiterates an Overweight rating on the shares. The target bump s primarily the result of an "enhanced conviction" in company's total address market expansion efforts, based on recent dementia-related psychosis data and a $250M capital raise, Duncan tells investors in a research note.
News For ACAD From the Last 2 Days
There are no results for your query ACAD
